You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,765,640


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,765,640 protect, and when does it expire?

Patent 10,765,640 protects ZTLIDO and is included in one NDA.

This patent has twenty-three patent family members in eighteen countries.

Summary for Patent: 10,765,640
Title:Non-aqueous patch
Abstract: [Problem] If lidocaine is composed of non-aqueous patch, the adhesive power of the preparation tends to get lower, as the composition amount of lidocaine is higher. It is popular to solve lidocaine in dissolving agent in order to compose lidocaine in patch and release effective amount into skin. However, if the amount of dissolving agent gets higher, the adhesive power gets extremely lower, so that an long-time attachment is difficult. [Solution] A non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent which are contained in a base of plaster, the plaster being hold by a support, of which strength of 50% stretched to longitudinal direction is less than 2,000 g/50 mm and of biaxially-oriented stretch cloth.
Inventor(s): Mori; Tatsuya (Saga, JP), Saida; Naoyuki (Saga, JP)
Assignee: ITOCHU CHEMICAL FRONTIER Corporation (Tokyo, JP) OISHI KOSEIDO CO., LTD. (Saga, JP)
Application Number:14/346,794
Patent Claim Types:
see list of patent claims
Compound;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,765,640: A Comprehensive Guide

Introduction

Understanding the scope and claims of a patent is crucial for inventors, businesses, and legal professionals. This article delves into the details of United States Patent 10,765,640, focusing on its scope, claims, and the broader patent landscape.

Overview of the Patent

United States Patent 10,765,640, titled "Non-aqueous patch," pertains to a specific type of transdermal patch designed for the delivery of active pharmaceutical ingredients through the skin. Here is a brief overview:

  • Publication Number: US10765640B2
  • Application Number: US14/346,794
  • Inventors and Assignees: The patent details the inventors and the assignees, which are critical for understanding the ownership and rights associated with the patent[2].

Scope of the Patent

The scope of a patent defines what is protected by the patent claims. For US10765640B2, the scope includes:

Non-Aqueous Patch Composition

The patent describes a non-aqueous patch that solves the issue of dissolving active ingredients, such as lidocaine, in a dissolving agent to ensure effective release into the skin. This composition is designed to enhance the stability and efficacy of the patch[2][5].

Application and Benefits

The non-aqueous patch is intended for transdermal drug delivery, providing a controlled release of the active ingredient. This design offers several benefits, including improved patient compliance, reduced side effects, and enhanced therapeutic efficacy.

Claims of the Patent

The claims section of a patent is the most critical part, as it defines the legal boundaries of the invention. Here are some key aspects of the claims for US10765640B2:

Independent Claims

Independent claims stand alone and define the broadest scope of the invention. For this patent, these claims would typically include the basic components and structure of the non-aqueous patch.

Dependent Claims

Dependent claims build upon the independent claims and provide more specific details or variations of the invention. These claims might include specific materials used, the method of manufacturing, or particular applications of the patch.

Patent Landscape Analysis

To understand the position of US10765640B2 within the broader patent landscape, it is essential to analyze related patents and trends.

Prior Art and Related Patents

Using tools like the USPTO's Patent Public Search or international databases such as the European Patent Office's esp@cenet, one can identify prior art and related patents in the field of transdermal drug delivery. This helps in understanding how the current patent innovates beyond existing technologies[1].

Global Dossier and International Filings

The Global Dossier service provided by the USPTO allows users to view the patent family for a specific application, including related applications filed at participating IP Offices. This can reveal whether similar patents have been filed in other jurisdictions, indicating the global reach of the invention[1].

Citation Data and Office Actions

The Common Citation Document (CCD) application consolidates prior art cited by all participating offices for the family members of a patent application. This tool can help identify how US10765640B2 is positioned in terms of prior art and how it has been evaluated by different patent offices[1].

Impact on Patent Litigation

Patent litigation trends can provide insights into the potential risks and opportunities associated with a patent. For instance:

  • Patent Infringement Litigation: The increase in patent infringement lawsuits, particularly in the pharmaceutical and medical device sectors, highlights the importance of robust patent claims and thorough landscape analysis. The Leahy-Smith America Invents Act (AIA) has introduced changes that affect patent litigation, such as limiting the number of defendants in a lawsuit[4].

  • Non-Practicing Entities (NPEs): NPEs, which do not manufacture products but focus on licensing and enforcing patents, play a significant role in patent litigation. Understanding the role of NPEs can help in strategizing patent enforcement and defense[4].

Data and Statistics

Analyzing datasets such as the Patent Claims Research Dataset provided by the USPTO can offer detailed insights into patent claims and scope. This dataset includes information on claims from US patents granted between 1976 and 2014 and US patent applications published between 2001 and 2014. It helps in understanding trends and patterns in patent claims that can be applied to US10765640B2[3].

Practical Applications and Future Directions

The non-aqueous patch described in US10765640B2 has significant practical applications in the field of transdermal drug delivery. Here are some future directions:

  • Clinical Trials and Regulatory Approvals: The next steps would involve conducting clinical trials to validate the efficacy and safety of the patch. Regulatory approvals from bodies like the FDA would be crucial for market entry.

  • Market Competition: Analyzing the competitive landscape in the transdermal drug delivery market can help in positioning the product effectively. This includes understanding existing products, their limitations, and how the non-aqueous patch can offer superior benefits.

Key Takeaways

  • Patent Scope and Claims: Understanding the scope and claims of US10765640B2 is essential for protecting the invention and avoiding infringement.
  • Patent Landscape: Analyzing related patents and international filings helps in understanding the innovation's position within the broader patent landscape.
  • Litigation Trends: Being aware of patent litigation trends, especially in the pharmaceutical sector, is crucial for strategic planning.
  • Data Analysis: Utilizing datasets like the Patent Claims Research Dataset can provide valuable insights into patent trends and patterns.

FAQs

What is the main innovation of US10765640B2?

The main innovation of US10765640B2 is the development of a non-aqueous patch for transdermal drug delivery, which enhances the stability and efficacy of the active pharmaceutical ingredients.

How can I search for related patents?

You can use the USPTO's Patent Public Search tool or international databases like the European Patent Office's esp@cenet to search for related patents.

What is the significance of the Global Dossier service?

The Global Dossier service allows users to view the patent family for a specific application, including related applications filed at participating IP Offices, providing a comprehensive view of the patent's global reach.

How does the Common Citation Document (CCD) application help?

The CCD application consolidates prior art cited by all participating offices for the family members of a patent application, helping to identify how a patent is positioned in terms of prior art.

What are the implications of the Leahy-Smith America Invents Act (AIA) on patent litigation?

The AIA has introduced changes that affect patent litigation, such as limiting the number of defendants in a lawsuit, which can impact how patent infringement cases are filed and managed.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. Google Patents - US10765640B2: https://patents.google.com/patent/US10765640B2/es
  3. USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. GAO - Assessing Factors That Affect Patent Infringement Litigation: https://www.gao.gov/products/gao-13-465
  5. Unified Patents - US-20210038531-A1: https://portal.unifiedpatents.com/patents/patent/US-20210038531-A1

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,765,640

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Scilex Pharms ZTLIDO lidocaine PATCH;TOPICAL 207962-001 Feb 28, 2018 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,765,640

PCT Information
PCT FiledSeptember 27, 2011PCT Application Number:PCT/JP2011/072072
PCT Publication Date:April 04, 2013PCT Publication Number: WO2013/046335

International Family Members for US Patent 10,765,640

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil 112014006719 ⤷  Subscribe
Canada 2850024 ⤷  Subscribe
Cyprus 1120754 ⤷  Subscribe
Denmark 2823815 ⤷  Subscribe
European Patent Office 2823815 ⤷  Subscribe
European Patent Office 3363432 ⤷  Subscribe
Spain 2683006 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.